Cabergolina [Spanish]
Brand names,
Cabergolina [Spanish]
Analogs
Cabergolina [Spanish]
Brand Names Mixture
Cabergolina [Spanish]
Chemical_Formula
C26H37N5O2
Cabergolina [Spanish]
RX_link
http://www.rxlist.com/cgi/generic3/cabergoline.htm
Cabergolina [Spanish]
fda sheet
Cabergolina [Spanish]
msds (material safety sheet)
Cabergolina [Spanish]
Synthesis Reference
No information avaliable
Cabergolina [Spanish]
Molecular Weight
451.604 g/mol
Cabergolina [Spanish]
Melting Point
102 - 104 oC
Cabergolina [Spanish]
H2O Solubility
Insoluble
Cabergolina [Spanish]
State
Solid
Cabergolina [Spanish]
LogP
2.855
Cabergolina [Spanish]
Dosage Forms
Tablets for oral administration (0.5 mg)
Cabergolina [Spanish]
Indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
Cabergolina [Spanish]
Pharmacology
Cabergoline is a dopamine receptor agonist and uncategorized drug which suppresses the production of prolactin in pituitary gland. It is an ergot-derivative. It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs such as reduced libido and anorgasmia. It also has been suggested online that it has a possible recreational use in reducing or eliminating the male refractory period.
Cabergolina [Spanish]
Absorption
First-pass effect is seen, however the absolute bioavailability is unknown.
Cabergolina [Spanish]
side effects and Toxicity
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations.
Cabergolina [Spanish]
Patient Information
Cabergolina [Spanish]
Organisms Affected
Humans and other mammals